西 安 康 拓 医 疗 技 术 股 份 有 限 公 司 2025 年 度 提 质 增 效 重 回 报专 项行 动 方案 的半 年 度 评 估 报 告 西安康拓医疗技术股份有限公司（以下简称"公司"或"康拓医疗"）以 2025 年既定发展蓝图为指引，极响应交易所关于科创板上市公司"提质增效重回报" 专项行动的号召，为提振市场信心、保障资本市场平稳运行以及为推动经济实现 高质量跃升发挥积极作用，以更为笃定的姿态踏入高质量发展新阶段，将各项工 作目标细化分解、精准落地。截至 2025 年半年度，公司在公司治理、经营策略 以及回馈投资者等关键领域，开展了一系列针对性强、实效性高的工作举措。 一、持续聚焦主业，拓展市场边界 在神经外科产品首次面临区域集中采购带来的挑战与机遇背景下，公司 2025 年半年度加速推进 PEEK 材料产品的市场下沉，通过优化渠道布局强化市 场渗透力，持续夯实主营业务根基并拓展其发展边界。公司持续深化在三类植入 医疗器械领域的竞争优势，重点聚焦神经外科、颌面修复、皮肤填充、心胸外科、 口腔科等医疗板块，通过加大技术研发投入与市场开拓力度，构建更具竞争力的 产品矩阵。 在全球化布局方面，公司积极 ...

西安康拓医疗技术股份有限公司 关于向参股公司提供财务资助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 西安康拓医疗技术股份有限公司（以下简称"公司"或"康拓医疗") 拟以自有资金向参股公司 BRANCHPOINT &AURA DEVELOPMENT LLC（以下 简称"BRANCHPOINT"或"资助对象"）提供不超过 200 万美元的财务资助。 财务资助期限自公司股东会决议通过之日起不超过 1 年。公司拟授权管理层在上 述财务资助额度内根据该参股公司实际经营需求办理财务资助事宜。本次财务资 助按照 5%/年计息。 证券代码：688314 证券简称：康拓医疗 公告编号：2025-035 履行的审议程序：本次财务资助事项已经公司第二届董事会第十八次会 议审议通过，尚需提交股东会审议。本次财务资助对象不属于公司合并报表范围 内子公司，不构成关联交易。 1 助事宜。 本事项已经公司第二届董事会第十八次会议、第二届董事会第十四次审计委 员会审议通过，本事项尚需提交公司股东会审议。 本次拟提供财务资助事项不会影 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2025-033 西安康拓医疗技术股份有限公司 关于召开 2025 半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 （二）会议召开地点：上证路演中心 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 9 月 10 日（星期三）至 9 月 16 日（星期二）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 public@kontmed.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 西安康拓医疗技术股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发布公司 2025 半年度报告，为便于广大投资者更全面深入地了解公司 2025 半年度经营成果、财务状况，公司计划于 2025 年 9 月 17 日（星期三）14:00-15:00 举行 2025 半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 半年度的经营 ...

证券代码：688314 证券简称：康拓医疗 公告编号：2025-031 西安康拓医疗技术股份有限公司 2025年半年度募集资金存放、管理与实际使用情况 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 募集资金基本情况 （一） 实际募集资金金额和资金到账时间 经中国证券监督管理委员会出具的《关于同意西安康拓医疗技术股份有限公 司首次公开发行股票注册的批复》（证监许可[2021]959 号）核准，并经上海证 券交易所同意，公司首次公开发行人民币普通股（A 股）1,451.00 万股。募集资 金总额为人民币 251,603,400.00 元，扣除不含税的发行费用人民币 43,355,571.58 元，募集资金净额为人民币 208,247,828.42 元。本次募集资金已于 2021 年 5 月 13 日全部到位，中审众环会计师事务所（特殊普通合伙）于 2021 年 5 月 13 日 对资金到位情况进行了审验，并出具了《验资报告》（众环验字[2021] 0800005 号）。 公司已按照相关规定对募集资金采取了专 ...

西安康拓医疗技术股份有限公司 关于收购西安蝾螈生物技术有限公司部分 股权及西安惠才企业管理咨询合伙企业（有 限合伙）部分财产份额的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 西安康拓医疗技术股份有限公司（以下简称"公司"或"康拓医疗"）拟 以自有或自筹资金通过新设全资子公司分别收购高宗贤持有的西安蝾螈生物技 术有限公司（以下简称"蝾螈生物"或"标的公司 1"）55.4999%的股权以及高 宗贤、刘芷昕、王亮、郜香黎（以下合称"交易对方"）合计持有蝾螈生物股东 西安惠才企业管理咨询合伙企业（有限合伙）（以下简称"西安惠才"或"标的 公司 2"）72.9931%的财产份额，本次交易价格合计为人民币 84,982,489.00 元。 本次交易完成后，公司及新设全资子公司将直接持有蝾螈生物 63.0001%的股权， 将通过持有西安惠才 898.75 万元财产份额间接持有蝾螈生物 27.0074%的股权， 上述合计持有蝾螈生物 90.0075%的股权，蝾螈生物将成为公司的控股子公司， 纳入公司合并财务报表范 ...

Group 1 - The company announced a revenue of 170 million yuan for the first half of 2025, representing a year-on-year growth of 11.07% [1] - The net profit for the same period was 54.9986 million yuan, showing a year-on-year increase of 12.72% [1] - The company plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders, amounting to a total cash dividend of 16.2478 million yuan (including tax) [1]

Group 1 - The core point of the news is that Kangtuo Medical experienced a decline of 5.15% in its stock price, reaching 37.17 yuan per share, with a total market capitalization of 3.02 billion yuan [1] - Kangtuo Medical, established on March 14, 2005, and listed on May 18, 2021, specializes in the research, production, and sales of three types of implantable medical devices [1] - The revenue composition of Kangtuo Medical includes 63.94% from PEEK material neurosurgical products, 22.42% from titanium material neurosurgical products, 10.47% from other products, and 3.18% from supplementary products [1] Group 2 - According to data, a fund under Jianxin Fund holds a significant position in Kangtuo Medical, with Jianxin Flexible Allocation Mixed A (000270) owning 106,700 shares, representing 1.18% of the fund's net value [2] - The Jianxin Flexible Allocation Mixed A fund has a total scale of 112 million yuan and has achieved a return of 49.44% this year, ranking 464 out of 8190 in its category [2] - The fund has also seen a remarkable return of 99.9% over the past year, ranking 298 out of 7966 in its category, and a cumulative return of 152.36% since its inception [2] Group 3 - The fund manager of Jianxin Flexible Allocation Mixed A is Ye Letian, who has a tenure of 13 years and 164 days, with the fund's total asset scale at 6.53 billion yuan [3] - During Ye Letian's tenure, the best fund return was 241.01%, while the worst was -18.94% [3] - The co-manager, Guo Zhiteng, has a tenure of 1 year and 266 days, managing a fund scale of 625 million yuan, with a best return of 155.31% and a worst return of 12.27% during his tenure [3]

Group 1 - The core viewpoint of the news is that Kangtuo Medical has shown stable trading activity with a slight increase in financing and a notable balance in margin trading as of August 26 [1] - On August 26, Kangtuo Medical's stock price remained unchanged at 0.00%, with a trading volume of 105 million yuan and a financing buy-in amount of 16.49 million yuan, while the financing repayment was 20.12 million yuan, resulting in a net financing outflow of 3.62 million yuan [1] - As of August 26, the total margin trading balance for Kangtuo Medical was 133 million yuan, which accounts for 4.10% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of March 31, the number of shareholders for Kangtuo Medical increased by 10.54% to 4,435, while the average circulating shares per person decreased by 9.54% to 18,317 shares [2] - For the first quarter of 2025, Kangtuo Medical reported a revenue of 82.49 million yuan, representing a year-on-year growth of 17.98%, and a net profit attributable to shareholders of 24.05 million yuan, which is a 20.63% increase year-on-year [2] - Since its A-share listing, Kangtuo Medical has distributed a total of 152 million yuan in dividends, with 85.42 million yuan distributed over the past three years [3]

Core Insights - The financing balance of the Sci-Tech Innovation Board increased by 479 million yuan compared to the previous trading day, while the margin trading balance decreased by 16.67 million yuan [1] - As of August 8, the total margin trading balance on the Sci-Tech Innovation Board reached 180.87 billion yuan, marking a continuous increase for 20 trading days [1] - The stock with the highest financing balance is SMIC, with a latest financing balance of 7.577 billion yuan [1] Financing Balance Summary - The total financing balance on the Sci-Tech Innovation Board is 180.27 billion yuan, with a daily increase of 479 million yuan [1] - 284 stocks saw an increase in financing balance, while 300 stocks experienced a decrease [1] - Notable increases in financing balance include Kangtuo Medical (29.39%), Gongda High-Tech (25.38%), and Aerospace Universe (20.30%) [1] Margin Trading Balance Summary - The stock with the highest margin trading balance is Cambricon Technologies, with a latest balance of 20 million yuan [2] - 96 stocks saw an increase in margin trading balance, while 179 stocks experienced a decrease [2] - Significant increases in margin trading balance include Ruikeda (444.09%), KQ Bio (137.60%), and Youkede (56.17%) [2]

Core Viewpoint - The medical device industry experienced a slight increase of 0.93% on August 8, with a net outflow of 611 million yuan in main capital, indicating a mixed performance among constituent stocks [1] Group 1: Market Performance - A total of 59 constituent stocks rose while 39 fell, reflecting a generally positive sentiment despite the capital outflow [1] - The main capital outflow was led by Anbiping with 11.75 million yuan, followed by Dongfulong with 10.71 million yuan, and Anjiasi with 9.95 million yuan [1] Group 2: Notable Stocks - Mindray Medical (code: 300760) had a latest price of 230.71 yuan with a slight decrease of 0.03% and a net inflow of 107 million yuan, accounting for 7.18% of the main capital [1] - Lepu Medical (code: 300003) saw a price of 17.27 yuan, an increase of 6.93%, with a net inflow of 107 million yuan, representing 5.73% of the main capital [1] - Meihua Medical (code: 300136) reported a price of 20.03 yuan, up by 7.17%, with a net inflow of 559.96 million yuan, which is 11.04% of the main capital [1] - Kangdelai (code: 603987) had a price of 9.23 yuan, increasing by 5.73%, with a net inflow of 485.15 million yuan, making up 12.43% of the main capital [1] - Other notable stocks include Baikang (code: 688068) with a price of 42.58 yuan and a net inflow of 394.93 million yuan, and Sainuo Medical (code: 688108) with a price of 20.44 yuan, up by 20.02%, and a net inflow of 2762.62 million yuan [1]